These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2653024)

  • 1. Extent of cisplatin formation in carboplatin admixtures.
    Perrone RK; Kaplan MA; Bogardus JB
    Am J Hosp Pharm; 1989 Feb; 46(2):258-9. PubMed ID: 2653024
    [No Abstract]   [Full Text] [Related]  

  • 2. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge.
    Lenz K; Hann S; Koellensperger G; Stefanka Z; Stingeder G; Weissenbacher N; Mahnik SN; Fuerhacker M
    Sci Total Environ; 2005 Jun; 345(1-3):141-52. PubMed ID: 15919535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrospray ionization mass spectrometry of platinum anticancer agents.
    Poon GK; Mistry P; Lewis S
    Biol Mass Spectrom; 1991 Nov; 20(11):687-92. PubMed ID: 1799578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
    Cheung YW; Cradock JC; Vishnuvajjala BR; Flora KP
    Am J Hosp Pharm; 1987 Jan; 44(1):124-30. PubMed ID: 3548341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, analytical and pharmacokinetic aspects in cancer chemotherapy with platinum coordination compounds.
    Caroli S; Alimonti A; Petrucci F; La Torre F; Dominici C; Castello MA
    Ann Ist Super Sanita; 1989; 25(3):487-97. PubMed ID: 2696394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection.
    Lemma T; Mandal R; Li XF; Pawliszyn J
    J Sep Sci; 2008 Jun; 31(10):1803-9. PubMed ID: 18446809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects].
    Dominici C; Petrucci F; Alimonti A; La Torre F; Cifani A; Caroli S
    Ann Ist Super Sanita; 1995; 31(2):289-94. PubMed ID: 8561393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
    Oprea A; Bazzazi H; Kangarloo B; Wolff JE
    Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whither carboplatin? A replacement for or an alternative to cisplatin?
    Gil A
    J Clin Oncol; 1987 Dec; 5(12):2041-2. PubMed ID: 3316520
    [No Abstract]   [Full Text] [Related]  

  • 12. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents.
    Lenz K; Koellensperger G; Hann S; Weissenbacher N; Mahnik SN; Fuerhacker M
    Chemosphere; 2007 Nov; 69(11):1765-74. PubMed ID: 17624406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
    Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
    Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
    Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL; Reed E
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical status of carboplatin.
    Canetta R; Franks C; Smaldone L; Bragman K; Rozencweig M
    Oncology (Williston Park); 1987 Jul; 1(5):61-70. PubMed ID: 3079484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platinum complexes as potential antineoplastic drugs].
    Kuduk-Jaworska J
    Postepy Hig Med Dosw; 1984; 38(3):281-322. PubMed ID: 6398870
    [No Abstract]   [Full Text] [Related]  

  • 19. On-line differential pulse polarographic detection of carboplatin in biological samples after chromatographic separation.
    Elferink F; van der Vijgh WJ; Pinedo HM
    Anal Chem; 1986 Sep; 58(11):2293-6. PubMed ID: 3532865
    [No Abstract]   [Full Text] [Related]  

  • 20. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
    Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
    Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.